Determinants of persistent symptoms after treatment for Lyme borreliosis: a prospective observational cohort study.

"Declaration of interests MEB, FRvdS and JWH report collaborations on LB diagnostics with Pfizer, Antigen Discovery Inc., Oxford Immunotec, AID/GenID, and InVitaLab; funding to institution and/or material supplied for research free of charge, no personal financial compensation. MEB reports support for travel expenses related to LB symposium at Massachusetts General Hospital. LABJ and BJK are co-inventor of Spirofind, an experimental in-house assay for Lyme borreliosis, which is owned by Radboudumc and will not be developed further as potential diagnostic test. CCvdW is a consortium partner and partner in sub-project in the NMCB consortium (The Dutch ME/CFS Cohort and Biobank Consortium) funded by Netherlands Organization for Health Research and Development (ZonMw, project numbers 10091012110027 and 10091012110018). The other authors report no competing interests."

"We gratefully acknowledge the following persons for their contributions to this study: G.H.J. van Arkel, M. Becker-Stynenbosch, R. van Boxtel, M.A.E. Brouwer, H. Dijkstra, A.R.T. Donders, J. Ersöz, E. Franz, I. Friesema, D. de Haan, R. Hartman, L. van der Hoeven, H. ter Hofstede, M.N. Hoogerwerf, H. ten Hulscher, M. Jonker, M. Kerstholt, B. Koetsier, B. van Kooten, B.A. Lemkes, H. Lemmers, C.D.M. Nijhuis, G.A. Oei, J.H.J. Reimerink, M. Starink, C. Uittenbosch, A. van Vliet, H. van Weert, A. Wijmenga, M. Zwerink; and all the study participants. The LymeProspect study was funded by the 10.13039/501100001826Netherlands Organisation for Health Research and Development, (ZonMw) (project number 522001003), and the 10.13039/501100002999Dutch Ministry of Health, Welfare and Sport, (VWS)."